Introduction: The Hypogonadism Impact of Symptoms Questionnaire (HIS-Q) is a patient-reported outcome measurement designed to comprehensively evaluate the symptoms of hypogonadism and to detect changes in these symptoms in response to treatment. Aim: To conduct item analysis and reduction, evaluate the psychometric properties of the HIS-Q, and provide guidance on interpreting the instrument score. Methods: A 12-week observational, longitudinal study of hypogonadal men was conducted. Participants completed the HIS-Q every 2 weeks. Blood samples were collected to evaluate testosterone levels. Participants also completed the Aging Male's Symptoms Scale, the International Index of Erectile Function, the Short Form-12 Health Survey, and the Patient-Reported Outcomes Measurement Information System Sexual Activity, Satisfaction with Sex Life, Sleep Disturbance, and Applied Cognition Scales (at baseline and weeks 6 and 12). Clinicians completed the Clinical Global Impression of Severity and Change measurements and a clinical form. Main Outcome Measures: Individual item performance was evaluated using descriptive statistics and Rasch analyses. Reliability (internal consistency and test-retest), validity (concurrent and know groups), and responsiveness were assessed. Results: In total, 177 men participated in the study (mean age ¼ 54.1 years, range ¼ 23e83). The original 53-item draft HIS-Q was reduced to 28 items; the final instrument included five domains (sexual, energy, sleep, cognition, and mood) with two sexual subdomains (libido and sexual function). For all domains, test-retest reliability was acceptable (intraclass correlation coefficients > 0.70), construct validity was good (jr > 0.30j for all comparisons). Known-groups validity was demonstrated for all HIS-Q domain scores, subdomain scores, and the total score as measured by the Clinical Global Impression of Severity, and total testosterone level at baseline (P < .05 for all comparisons). All domains and subdomains were responsive to change based on patientrated anchor questions (P < .05 for all comparisons). Conclusion: The final 28-item HIS-Q is reliable, valid, and responsive. The HIS-Q is suitable for inclusion in future clinical trials to help characterize the effects of testosterone replacement therapy.
INTRODUCTION
Hypogonadism is associated with a range of symptoms, including decreased libido, erectile dysfunction, decreased energy, sleep disturbance, and changes in mood. 1 Many of these symptoms are difficult to evaluate clinically and are best assessed through patient-reported outcome (PRO) measurements. There are several existing PRO instruments that have been used to evaluate the symptoms and effects of hypogonadism, such as the Psychosexual Daily Questionnaire, 2 the Aging Males Symptoms Scale (AMS), 3 the Sexual Arousal, Interest, and Drive Scale, and the Hypogonadism Energy Diary. 4 Although each of these instruments is useful in specific contexts, and some are well known, each is limited in at least one way. Specifically, all were not designed to assess hypogonadism comprehensively, have not been validated, and/or have not been developed according to regulatory standards.
The Hypogonadism Impact of Symptoms Questionnaire (HIS-Q) is a PRO instrument that was designed to assess changes in symptoms in hypogonadal men in response to testosterone replacement therapy (TRT). 5 The instrument was developed primarily for use in clinical trial settings, has been developed in accordance with the Food and Drug Administration's PRO guidance for industry, and addresses the limitations of existing instruments. 6 Development was informed by a literature review, input from clinicians, and qualitative studies with patients aimed at comprehensively identifying the symptoms of the condition. 5 The original draft HIS-Q was a 53-item questionnaire with a conceptual framework that included sexual, physical signs and symptoms, energy, sleep, cognitive, and mood domains. Results from the initial qualitative work in hypogonadal patients indicated that the HIS-Q was a comprehensive measurement of hypogonadal symptoms in men. The HIS-Q reflected the varied symptom experiences of patients, and the content validity of the instrument was confirmed. 5 
METHODS

Aims
The present study was designed as a stand-alone, 12-week, longitudinal, observational validation study of hypogonadal men for informing item reduction, developing scoring and scaling, and evaluating the psychometric properties of the HIS-Q. The primary objective of this study was to develop a final version of the HIS-Q of appropriate length for use in clinical trials, with an established scoring algorithm and acceptable psychometric properties (ie, reliability, validity, and responsiveness).
Participants
Twenty U.S. clinical sites participated in the study. Eligible participants who signed informed consents included men who were at least 18 years old; diagnosed with hypogonadism (serum total testosterone concentration < 300 ng/dL before enrollment); switching TRT treatments or on maintenance therapy or were treatment naïve; and able to understand English. Patients were excluded if they had non-stabilized depression (stabilized was defined as on the same antidepressant medication at the same dosage for !3 months), severe psychiatric illness, or addictions; history of or current obstructive sleep apnea; a clinically significant medical condition; or taking a concurrent medication that would affect hormonal balance or sexual functioning (eg, phosphodiesterase type 5 inhibitors) or interfere with participants' participation in the study.
Procedures and Measurements
The study protocol and procedures used were reviewed and approved by the appropriate institutional review committee (Ethical and Independent Review Services Institutional Review Board, September 25, 2013, protocol 13110-01). All study staff at every site were trained using a standardized training protocol on the purpose and procedures for the study. Participants completed in-person study visits at baseline, week 2, and week 12. The first assessment was completed during their first in-clinic visit (baseline), and subsequent assessments were completed at home every 2 weeks from week 2 through week 12. All PRO assessments were completed on an electronic PRO device. A subset of participants also completed a daily diary from baseline to day 28. The schedule of study assessments and a description of each is presented in Table 1. 3,7e11 Testosterone levels were assessed through blood draws from all participants at baseline and from participants who were beginning treatment or switching to a different treatment at weeks 2 and 12. Blood serum samples were processed and analyzed by a central laboratory (Total Testosterone: AbbVie, Inc., North Chicago, IL, USA; Free Testosterone: PPD Laboratories, Middleton, WI, USA) using liquid chromatography and tandem mass spectrometry and equilibrium dialysis to assess total and free testosterone levels, respectively.
Statistical Analyses
Descriptive statistics were used to characterize the sociodemographic and clinical characteristics of the sample. Item-level descriptive statistics (means, SD, median, range, frequency) were used to evaluate the performance of individual HIS-Q items. Then, exploratory factor analyses were used to analyze the factor structure of the instrument. Rasch analyses 12 were used to evaluate individual item and subscale properties. Exploratory factor analyses and Rasch analyses were conducted using SAS (SAS Institute, Cary, NC, USA) and RUMM2030, 13 respectively.
These analyses were conducted iteratively and the results were used to reduce the item pool and establish subscales and a scoring algorithm for the reduced HIS-Q. Items were flagged for consideration as deletion candidates based on descriptive item analyses (>50% floor and ceiling effects, high inter-item correlations > 0.80 and/or low item-total correlations < 0.20), factor analyses (weak factor loadings < 0.40, poor model fit), and Patients did not come to the sites for study-related visits during these weeks but did complete study questionnaires on the electronic patient-reported outcomes device at home at each of these time points. ‡ Only patients on new treatment had study-related blood draws at visits 2 and 3. § Sites reported any additional serum testosterone blood sample results that were independent of the study blood draws at each visit. Rasch analyses (item misfit, disordered thresholds). Item reduction decisions also considered previous qualitative research findings (ie, concept elicitation, content validity, etc) and input from expert clinicians on the clinical relevance and importance of items.
After item pool reduction and scoring algorithm establishment, the psychometric properties of the HIS-Q were evaluated. Internal consistency reliability of the HIS-Q domains was evaluated using the Cronbach a coefficient 14 at baseline, week 6, and week 12, with reliability values of at least 0.70 denoting a more homogeneous scale. 15 Test-retest reliability was assessed using intraclass correlation coefficients and paired-sample t-tests for all HIS-Q domain scores and the total score to examine HIS-Q stability over time within a stable subsample. Stable subjects were those with "no change" in relevant anchor questions and Clinical Global Impression (CGI) for Change from baseline to week 2; intraclass correlation coefficients of at least 0.7 indicate good test-retest reliability, coefficients from 0.4 to 0.7 indicate moderate test-retest reliability, and coefficients less 0.4 indicated low test-retest reliability. 15, 16 Convergent and divergent validity of the HIS-Q was assessed using Pearson product-moment and Spearman rank correlation coefficients to estimate the relation between HIS-Q domains and other conceptually relevant measurements (eg, higher correlations among HIS-Q sexual domains and Patient-Reported Outcomes Measurement Information System [PROMIS] and AMS sexual scales, HIS-Q energy domain and AMS SomatoVegetative Scale and Short Form-12 Health Survey vitality item, HIS-Q sleep domain and PROMIS sleep, HIS-Q cognition domain and PROMIS cognition, HIS-Q mood domain and AMS psychological). To assess known-groups validity, mean domain scores on the HIS-Q were analyzed by disease severity (CGI for Severity) and total testosterone was analyzed by analysis of variance.
Responder definitions were identified for the HIS-Q domains, subdomains, and total score using anchor-based and distributionbased methods. Mean scores for each HIS-Q domain and subdomain for participants who improved by one point on each concept-specific anchor question were used to establish anchorbased responder definitions. The SD at baseline (0.2, 0.3, and 0.5 times estimates) and the standard error of measurement 17, 18 were used to establish distribution-based responder definitions. A triangulation process considering anchor-and distribution-based definitions was used to derive final responder definitions of clinically meaningful change for each of the HIS-Q domain and subdomain scores.
RESULTS
In total, 196 patients were recruited into the study; a final analysis sample of 177 patients included all participants who had HIS-Q and clinical data at baseline (baseline, n ¼ 177; week 2, n ¼ 163; week 4, n ¼ 166; week 6, n ¼ 162; week 8, n ¼ 157; week 10, n ¼ 160; week 12, n ¼ 156). Participants were recruited from 20 clinical sites in 14 different states across the United States (mean number of patients per site ¼ 9.9, SD ¼ 4.6). Participants included 47 men who were new to TRT, 41 men who were switching from one TRT to another, and 89 maintenance patients who were on TRT at the time of enrollment and had no plans to change their treatment.
Demographics and Clinical Characteristics
The mean age of study participants was 54.1 years (SD ¼ 11.4), and most participants were white (74.0%) and were involved in an intimate relationship (82.5%; Table 2 ). Average time since hypogonadism diagnosis was 2.8 years (SD ¼ 2.2), with almost half the study participants classified by their providers as having a primary acquired etiology (45.8%; Table 3 ). Average body mass index of the study sample was 30.2 (SD ¼ 5.2). Baseline mean total and free testosterone levels for all tested participants were 507.6 ng/dL (SD ¼ 495.4) and 15.0 ng/dL (SD ¼ 15.9), respectively. Baseline AMS scores indicated that participants on maintenance therapy had moderate levels of sexual impairment, whereas patients who were switching medications or were treatment naïve had severe sexual impairment (overall mean ¼ 11. 
HIS-Q Item Evaluation and Item Reduction
The individual item-level analyses demonstrated acceptable distribution of the HIS-Q item responses across response categories and good distributional characteristics. Minor issues (eg, floor effects, high inter-item correlations, disordered thresholds, poor fit to the Rasch model) were noted for some items and taken into consideration during item reduction. For example, because expected items 15 (sexual activities enjoyable) and 16 (sexual activities satisfying) and items 22 (tired) and 23 (physically tired) were each highly correlated with each other. Thus, additional information (ie, factor loadings and Rasch results) was used to select the best-performing item from each pair. Other items performed poorly based on most item evaluation criteria and were eliminated.
Initially, a 30-item revised version of the instrument was established based on the item analyses; this included five numerical response items on frequency of sexual activities and an additional 25 ordinal response scale items in the sexual (n ¼ 7), physical signs and symptoms (n ¼ 2), energy (n ¼ 3), sleep (n ¼ 3), cognition (n ¼ 3), and mood (n ¼ 7) domains. However, psychometric analyses on this 30-item version of the HIS-Q indicated very poor psychometric characteristics for the physical signs and symptoms domain, and the two items from this domain were subsequently removed, yielding the final 28-item HIS-Q (Supplementary Appendix A) . This decision was supported by the clinical experts who assessed aspects of this domain using direct clinical measurements. . § Baseline serum total testosterone concentration lower than 300 ng/dL (n ¼ 68).
Supplementary Table 1 ). The cognition domain did not emerge as a distinct factor in this five-factor solution, but rather the cognition items loaded with the mood items.
Instrument scoring includes each of the 23 ordinal response scale items and yields five domain scores (sexual; energy, sleep, cognition, and mood) and two sexual subdomain scores (libido and sexual function). All 23 ordinal response scale items also can be used to yield a HIS-Q total score. The domain, subdomain, and total scores range from 0 to 100, with higher scores indicating greater dysfunction. No scoring is needed for the first five questions, because the items capture numerical data related to the frequency of sexual activity.
Psychometric Evaluation of the Final 28-Item HIS-Q
After item selection and development of the scoring algorithm, the psychometric properties of the final 28-item HIS-Q were evaluated.
Rasch Analyses
Rasch analyses were conducted on each of the HIS-Q domains and subdomains (n ¼ 117e171). Item performance was very good, with all items demonstrating fit to the Rasch model . These item thresholds were well matched to the distributions of individuals within each domain. There were a few minor issues with disordered thresholds (ie, some item response categories did not accurately distinguish between participants with different levels of hypogonadism severity) for three items, including "difficult achieving erections," "difficulty ejaculating," and "sad."
Reliability
The internal consistency reliability (ie, Cronbach a) was very good for the sexual symptoms domain (baseline ¼ 0. Test-retest reliability was assessed in those who were defined as stable based on patient-reported anchor questions from baseline to week 2. The ICCs were good for the sexual symptoms domain (0.81), libido subdomain (0.77), sexual function subdomain (0.80), energy domain (0.73), mood domain (0.87), and total score (0.80). Test-retest reliability was acceptable for the sleep (0.68) and cognition (0.68) domains.
Validity
There was strong evidence for convergent validity across all scales. The sexual domain and libido and sexual function subdomains were strongly correlated with the AMS Sexual Scale (r ¼ 0.65, 0.55, 0.55, respectively, P < .0001 for all comparisons), the International Index of Erectile Function Overall Satisfaction Score (r ¼ 0.68, 0.44, 0.67, P < .0001 for all comparisons), the PROMIS Sexual Activity Score (r ¼ À0.60, À0.74, À0.39, P < .0001 for all comparisons), and the PROMIS Global Satisfaction with Sex Life Score (r ¼ À0.65, À0.45, À0.60, P < .0001 for all comparisons). The energy domain was strongly correlated with the AMS Somato-Vegetative Scale (r ¼ 0.67, P < .0001) and the Short Form-12 Health Survey Vitality item (r ¼ À0.62, P < .0001). The sleep domain was strongly correlated with the PROMIS Sleep Disturbance score (r ¼ 0.75, P < .0001), the cognition domain was strongly correlated with the PROMIS Applied Cognition score (r ¼ À0.72, P < .0001), and the mood domain was strongly correlated with the AMS Psychological Scale (r ¼ 0.78, P < .0001). Divergent validity was demonstrated through low and non-significant correlations among conceptually unrelated scales (eg, HIS-Q energy, sleep, cognition, and mood domains with International Index of Erectile Function Orgasmic Function Scale; r ¼ 0.11e0.16).
The HIS-Q scores also were correlated with testosterone levels. At baseline, there were moderate correlations between total testosterone and the sexual domain (r ¼ À0.36, P < .0001), libido subdomain (r ¼ À0.29, P < .001), sexual function domain (r ¼ À0.32, P < .0001), energy domain (r ¼ À0.25, P < .001), and HIS-Q total score (r ¼ À0.34, P < .0001). Smaller but significant correlations were observed between total testosterone and sleep (r ¼ À0.17, P < .05), cognition (r ¼ À0.19, P < .05), and mood (r ¼ À0.18, P < .05) domains. A similar pattern of results with moderate correlations was observed between free testosterone levels and sexual, libido, sexual function, energy, and total scores (r ¼ À0.37 to À0.29, P < .001 for all comparisons).
Results demonstrated good known-group validity. All HIS-Q scores were significantly different when grouped according to clinician ratings of severity (P < .05 for all comparisons), and groups with greater clinician-rated severity also had significantly higher HIS-Q scores (Table 4) . Similarly, when grouped by total testosterone levels, significantly higher HIS-Q scores were observed in men with lower testosterone levels (P < .05 for all comparisons; Table 4 ).
Responsiveness
Changes in each of the patient-reported anchor questions were reflected by significant changes in the expected direction for all the HIS-Q scales (P < .05 for all comparisons; Table 5 ). Responsiveness also was assessed using changes based on the CGI for Severity; the sexual domain (P < .01), sexual function subdomain (P < .01), energy domain (P < .05), and HIS-Q total score (P < .01) showed significant trends in the expected direction from baseline to week 2 and from baseline to week 12 (Table 6 ). CGI-S ¼ Global ImpressioneSeverity; HIS-Q ¼ Hypogonadism Impact of Symptoms Questionnaire; LS ¼ least-squares; SE ¼ standard error. k P < .05; { P < .001; # P < .0001. *General linear model (PROC GLM). Pairwise comparisons between LS means were performed using the Scheffe test adjusting for multiple comparisons. † Pairwise comparisons: 1 ¼ no or very mild vs mild symptoms; 2 ¼ no or very mild vs moderate symptoms; 3 ¼ no or very mild vs severe symptoms; 4 ¼ mild vs moderate symptoms; 5 ¼ mild vs severe symptoms; 6 ¼ moderate vs severe symptoms. ‡ Pairwise comparisons: 1 ¼ <300 vs 300e500 ng/dL; 2 ¼ <300 vs >500 ng/dL; 3 ¼ 300e500 vs >500 ng/dL. J Sex Med 2016;13:1737e1749 Responder Definition Responder definitions were defined using anchor-and distribution-based methods. Anchor-based estimates were obtained from the mean scores for participants who improved by one point on the anchor questions for each domain (Table 5 ). The anchor-based and distribution-based responder estimates are presented in Figure 1, Figure 1) . Interpretation of the HIS-Q total score is complex, and the psychometric support for the contributing items and subscales varies; the responder definition for the HIS-Q total score is 7.0 (Figure 1 ).
DISCUSSION
The HIS-Q is a 28-item PRO instrument to assess changes in hypogonadal symptoms in response to TRT. The present study provides strong support for the psychometric properties of this newly developed instrument including the reliability, validity, and responsiveness in addition to information on the interpretation of the HIS-Q. To our knowledge, this is the first PRO that has been specifically developed for use in populations of hypogonadal men that comprehensively evaluates all the relevant domains, as identified through direct input from patients.
The HIS-Q demonstrated good correlations with other instruments designed to measure relevant domains of interest (eg, sexual, energy, mood, etc). These strong correlations and the comprehensive nature of the instrument suggest that it might be a useful end point in future studies evaluating TRT. The HIS-Q had moderate correlations with testosterone levels. Correlations between PRO and clinical measurements are often small to moderate in magnitude; this is expected because the value of a PRO measurement lies in gathering information from the patient that cannot be assessed through clinical measurements or other means.
It is important to note that the objective of this research was not to establish expected TRT treatment effects or estimate effects sizes for the instrument, but to ensure that the selected items performed appropriately for instrument finalization. Because of the observational study design and cohort selected for the present research (eg, many had relatively normal testosterone levels at baseline because the study required a "maintenance" group in which HIS-Q changes were not expected), reliable estimates of TRT treatment effects will need to be determined in future well-controlled studies.
Although it is possible to calculate a total score for the HIS-Q, this score should be carefully considered, adequately justified for specific research contexts, and interpreted with caution. Qualitative work results suggest that hypogonadism is highly heterogeneous in the symptoms experienced 5 and the psychometric properties vary across different HIS-Q domains. The HIS-Q domains measure distinct constructs and use of the composite HIS-Q total score as an end point might not capture treatment effects precisely. Analyzing specific domains of interest is recommended over using the total score. The sexual domain, libido and sexual function subdomains, and energy domain have the strongest psychometric properties and are likely the best outcome measurements for studies aiming to characterize TRT treatment effects.
The longer 2-week recall period was selected for the HIS-Q sexual domain because hypogonadal men often have lower levels of sexual activity and interest; thus, a longer period is appropriate to allow the opportunity for men to have relevant sexual experiences on which they can report. Shorter 1-week recall periods were selected for other domains. The recall periods that were selected for the HIS-Q domains are intended to strike a balance among accuracy of recall, respondent burden, and consideration for an adequate opportunity to engage in activities that form the basis for certain responses.
There were several limitations that should be noted. The etiology of hypogonadism for each patient participating in the study was not always known. In particular, the study team found that it was difficult to recruit patients with congenital secondary hypogonadism and those who were untreated. In addition, the men who participated in this study had testosterone levels that were not as low as expected at baseline, although the study was strengthened by the use of a central laboratory for the liquid chromatographic and tandem mass spectrometric testosterone testing. Moreover, some analyses in the present study (eg, exploratory factor analysis) could have benefited from a larger sample. Future studies of larger samples of men with hypogonadism will be used to further evaluate and confirm the factor structure of the HIS-Q. Future studies also will be aimed at further examining the performance properties of the HIS-Q and the relations of the instrument with clinical measurements in samples of symptomatic hypogonadal men with unequivocally low testosterone levels. It is important to note that the HIS-Q was neither designed nor tested as a screener for hypogonadism and its performance characteristics for this purpose are unknown.
CONCLUSIONS
The HIS-Q, a newly developed PRO instrument for the evaluation of hypogonadal symptoms, has demonstrated good reliability, validity, and responsiveness. The measurement has been developed in line with current Food and Drug Administration PRO guidance, and the final version of the measurement can be incorporated into TRT clinical trials. A shorter version of the instrument that lessens respondent burden and might be useful in clinical practice is currently under development.
